Foley Partner Paul Broude authored an article titled “The IPO Window Is Opening” in the March 2010 issue of MX: Medtech Executive. Broude examines the reasons for a device company to consider an initial public offering for its growth plans, stating that 2010 may bring the promise of IPOs for medical device companies to fund clinical trials, regulatory approvals, and the protection of the company’s intellectual property. He adds that going public enables some medical device and life science companies to continue growing while creating an exit vehicle for management and other shareholders.
Author(s)
Related Insights
16 January 2025
Blogs
Final Regulations for New Clean Energy Production and Investment Tax Credits
16 January 2025
Health Care Law Today
DEA Tightens Buprenorphine Telemedicine Prescribing Rules
The Drug Enforcement Administration and the U.S. Department of Health & Human Services just finalized their March 2023 proposed rule regarding telemedicine prescribing of buprenorphine.
16 January 2025
Innovative Technology Insights
President Biden Issues Second Cybersecurity Executive Order
This executive order builds upon EO 14028 to modernize the federal government’s cybersecurity posture while expanding on requirements imposed on third-party suppliers.